Advanced search
Publication Cover
mAbs Volume 15, 2023 - Issue 1
Submit an article Journal homepage
8,654
Views
6
CrossRef citations to date
0
Altmetric
Report

Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans

Hans Peter Grimma Roche Pharmaceutical Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, SwitzerlandView further author information
,
Vanessa Schumachera Roche Pharmaceutical Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, SwitzerlandView further author information
,
Martin Schäferb Roche Pharmaceutical Research and Early Development, Large Molecule Research, Roche Innovation Center Munich, Munich, GermanyView further author information
,
Sabine Imhof-Jungb Roche Pharmaceutical Research and Early Development, Large Molecule Research, Roche Innovation Center Munich, Munich, GermanyView further author information
,
Per-Ola Freskgårda Roche Pharmaceutical Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, SwitzerlandView further author information
,
Kevin Bradya Roche Pharmaceutical Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, SwitzerlandView further author information
,
Carsten Hofmanna Roche Pharmaceutical Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, SwitzerlandView further author information
,
Petra Rügerb Roche Pharmaceutical Research and Early Development, Large Molecule Research, Roche Innovation Center Munich, Munich, GermanyView further author information
,
Tilman Schlothauerb Roche Pharmaceutical Research and Early Development, Large Molecule Research, Roche Innovation Center Munich, Munich, GermanyView further author information
,
Ulrich Göpfertb Roche Pharmaceutical Research and Early Development, Large Molecule Research, Roche Innovation Center Munich, Munich, GermanyView further author information
,
Maximilian Hartlb Roche Pharmaceutical Research and Early Development, Large Molecule Research, Roche Innovation Center Munich, Munich, GermanyView further author information
,
Sylvia Rottachb Roche Pharmaceutical Research and Early Development, Large Molecule Research, Roche Innovation Center Munich, Munich, GermanyView further author information
,
Adrian Zwickb Roche Pharmaceutical Research and Early Development, Large Molecule Research, Roche Innovation Center Munich, Munich, GermanyView further author information
,
Shanon Segera Roche Pharmaceutical Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, SwitzerlandView further author information
,
Rachel Neffa Roche Pharmaceutical Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, SwitzerlandView further author information
,
Jens Niewoehnerb Roche Pharmaceutical Research and Early Development, Large Molecule Research, Roche Innovation Center Munich, Munich, GermanyView further author information
&
Niels Janssena Roche Pharmaceutical Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, Basel, SwitzerlandCorrespondence[email protected]
View further author information
 show all
Article: 2261509 | Received 10 May 2023, Accepted 18 Sep 2023, Published online: 12 Oct 2023

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Marlena Surowka & Christian Klein. (2024) A pivotal decade for bispecific antibodies?. mAbs 16:1.
Read now
Zixuan Zhao, Yun Liu, Shirong Ruan & Yixuan Hu. (2023) Current Anti-Amyloid-β Therapy for Alzheimer’s Disease Treatment: From Clinical Research to Nanomedicine. International Journal of Nanomedicine 18, pages 7825-7845.
Read now

Articles from other publishers (4)

Qin Huang, Ken Y. Chan, Jason Wu, Nuria R. Botticello-Romero, Qingxia Zheng, Shan Lou, Casey Keyes, Alexander Svanbergsson, Jencilin JohnstonAllan Mills, Chin-Yen Lin, Pamela P. BrauerGabrielle ClouseSimon PacouretJohn W. HarveyThomas BeddowJenna K. Hurley, Isabelle G. Tobey, Megan PowellAlbert T. Chen, Andrew J. Barry, Fatma-Elzahraa EidYujia A. Chan & Benjamin E. Deverman. (2024) An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery. Science.
Crossref
Thomas Gabriel Schreiner, Cristina Georgiana Croitoru, Diana Nicoleta Hodorog & Dan Iulian Cuciureanu. (2024) Passive Anti-Amyloid Beta Immunotherapies in Alzheimer’s Disease: From Mechanisms to Therapeutic Impact. Biomedicines 12:5, pages 1096.
Crossref
Jeffrey Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Fonseca & Feixiong Cheng. (2024) Alzheimer's disease drug development pipeline: 2024. Alzheimer's & Dementia: Translational Research & Clinical Interventions 10:2.
Crossref
Xiaolei Gu, Long Qi, Qing Qi, Jing Zhou, Song Chen & Ling Wang. (2024) Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets. BioScience Trends 18:1, pages 49-65.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.